Research Article
Clinical Efficacy and Safety of Bevacizumab, Apatinib, and Recombinant Human Endothelial Inhibitor in the Treatment of Advanced Gastric Cancer
Table 1
Comparison of general data of the four groups of patients (‾x ± s).
| Groups | Gender (male/female) (case) | Mean age (year) | Mean course of disease (months) | Stage (case) | IIIa | IIIb | IIIc | IV |
| Control group | 35/16 | 48.62 ± 6.87 | 4.61 ± 1.53 | 11 | 20 | 11 | 9 | Study I group | 32/19 | 51.04 ± 7.98 | 5.02 ± 2.31 | 10 | 22 | 10 | 9 | Study II group | 36/15 | 50.04 ± 5.34 | 4.87 ± 2.75 | 11 | 21 | 9 | 10 | Study III group | 34/17 | 49.77 ± 8.23 | 4.91 ± 1.83 | 12 | 19 | 10 | 10 | X2/F | 0.482 | 0.975 | 0.331 | 0.232 | 0.408 | 0.249 | 0.129 | | 0.546 | 0.406 | 0.803 | 0.975 | 0.939 | 0.969 | 0.988 |
|
|